MFOLFOX6 plus CEDIRANIB VS MFOLFOX6 plus BEVACIZUMAB IN PREVIOUSLY UNTREATED METASTATIC COLORECTAL CANCER (MCRC): A RANDOMIZED, DOUBLE-BLIND, PHASE II/III STUDY (HORIZON III)

被引：0
|
作者：
Schmoll, H. [1 ]
Cunningham, D. [2 ]
Sobrero, A. [3 ]
Karapetis, C. [4 ]
Rougier, P. [5 ]
Koski, S. L. [6 ]
Barker, P. [7 ]
Mookerjee, B. [7 ]
Robertson, J. [8 ]
van Cutsem, E. [9 ]
机构：
[1] Univ Halle Wittenberg, Dept Internal Med 4, Halle, Germany
[2] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England
[3] Osped San Martino Genova, Dept Med Oncol, Genoa, Italy
[4] Flinders Med Ctr, Adelaide, SA, Australia
[5] Hop Ambroise Pare, Boulogne Billancourt, France
[6] Univ Alberta, Cross Canc Inst, Edmonton, AB, Canada
[7] AstraZeneca, Wilmington, DE USA
[8] AstraZeneca, Macclesfield, Cheshire, England
[9] Univ Hosp Gasthuisberg, Dept Internal Med, B-3000 Louvain, Belgium
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：189 / 189
页数：1
相关论文
共 50 条
  • [1] Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer
    D Cunningham
    R P W Wong
    G D'Haens
    J-Y Douillard
    J Robertson
    A M Stone
    E Van Cutsem
    British Journal of Cancer, 2013, 108 : 493 - 502
  • [2] Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer
    Cunningham, D.
    Wong, R. P. W.
    D'Haens, G.
    Douillard, J-Y
    Robertson, J.
    Stone, A. M.
    Van Cutsem, E.
    BRITISH JOURNAL OF CANCER, 2013, 108 (03) : 493 - 502
  • [3] Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III)
    Schmoll, Hans-Joachim
    Cunningham, David
    Sobrero, Alberto
    Karapetis, Christos S.
    Rougier, Philippe
    Koski, Sheryl L.
    Kocakova, Ilona
    Bondarenko, Igor
    Bodoky, Gyoergy
    Mainwaring, Paul
    Salazar, Ramon
    Barker, Peter
    Mookerjee, Bijoyesh
    Robertson, Jane
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (29) : 3588 - 3595
  • [4] A randomized phase II study of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab for previously untreated, liver-limited metastatic colorectal cancer that is unsuitable for resection (ATOM trial).
    Uetake, Hiroyuki
    Emi, Yasunori
    Yamanaka, Takeharu
    Muro, Kei
    Oki, Eiji
    Takahashi, Takao
    Nagasaka, Takeshi
    Hatano, Etsuro
    Ojima, Hitoshi
    Manaka, Dai
    Kusumoto, Tetsuya
    Katayose, Yu
    Fujiwara, Toshiyoshi
    Yoshida, Kazuhiro
    Unno, Michiaki
    Hyodo, Ichinosuke
    Tomita, Naohiro
    Sugihara, Kenichi
    Maehara, Yoshihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [5] PEAK: A randomized phase II study to compare the efficacy of panitumumab plus mFOLFOX6 to bevacizumab plus mFOLFOX6 in patients (pts) with previously untreated, unresectable metastatic colorectal cancer (mCRC) expressing wild-type KRAS
    Schwartzberg, L. S.
    Wagner, V. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [6] A randomized study of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 as first-line treatment for unresectable metastatic colorectal cancer
    Belhadef, S.
    Arab, A.
    Belmadi, M.
    Beninal, M.
    Bacha, N.
    Abdallah, R.
    Mechta, K.
    Dahmane, A.
    Mahfouf, H.
    Oukkal, M.
    Bouzid, K.
    Faraqun, S.
    Bentabak, K.
    Younes, S. Ait
    ANNALS OF ONCOLOGY, 2020, 31 : S92 - S92
  • [7] BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer
    Benson, Al B., III
    Kiss, Igor
    Bridgewater, John
    Eskens, Ferry A. L. M.
    Sasse, Carolyn
    Vossen, Sandra
    Chen, Jihong
    Van Sant, Chip
    Ball, Howard A.
    Keating, Anne
    Krivoshik, Andrew
    CLINICAL CANCER RESEARCH, 2016, 22 (20) : 5058 - 5067
  • [8] A Phase I/II, Open-label, Randomised Study of BIBF 1120 Plus mFOLFOX6 Compared to Bevacizumab Plus mFOLFOX6 in Patients with Metastatic Colorectal Cancer
    Van Cutsem, E.
    Prenen, H.
    Guillen-Ponce, C.
    Bennouna, J.
    Di Benedetto, M.
    Bouche, O.
    Staines, H.
    Oum'Hamed, Z.
    Studeny, M.
    Capdevila, J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : 8 - 9
  • [9] SUNITINIB PLUS 5-FLUOROURACIL, LEUCOVORIN AND OXALIPLATIN (MFOLFOX6) VS. BEVACIZUMAB PLUS MFOLFOX6 IN FRST-LINE METASTATIC COLORECTAL CANCER (MCRC) - INTERIM RESULTS OF A RANDOMIZED, PHASE IIB STUDY
    Hecht, J.
    Yoshino, T.
    Mitchell, E.
    Dees, M.
    Kroening, H.
    Patel, R.
    Welslau, M.
    Dakhil, S.
    Yamazaki, K.
    Maneval, Chow E.
    Kretzschmar, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 15 - 15
  • [10] SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer
    van Hazel, Guy A.
    Heinemann, Volker
    Sharma, Navesh K.
    Findlay, Michael P. N.
    Ricke, Jens
    Peeters, Marc
    Perez, David
    Robinson, Bridget A.
    Strickland, Andrew H.
    Ferguson, Tom
    Rodriguez, Javier
    Kroening, Hendrik
    Wolf, Ido
    Ganju, Vinod
    Walpole, Euan
    Boucher, Eveline
    Tichler, Thomas
    Shacham-Shmueli, Einat
    Powell, Alex
    Eliadis, Paul
    Isaacs, Richard
    Price, David
    Moeslein, Fred
    Taieb, Julien
    Bower, Geoff
    Gebski, Val
    Van Buskirk, Mark
    Cade, David N.
    Thurston, Kenneth
    Gibbs, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15) : 1723 - +
12345